hsa-mir-127: Hsa-mir-127 is a microRNA that has been implicated in the pathogenesis of Epstein-Barr virus (EBV)-positive Burkitt lymphoma (BL) [PMC3432484]. EBV is a virus that infects humans and persists in the body without causing disease in about 90% of adults [5]. However, EBV is associated with the development of various malignancies, including nasopharyngeal carcinoma and Hodgkin's lymphoma [4]. In EBV-positive BL, the virus is present in more than 90% of cases [26]. While BL has been considered a tumor of germinal center (GC) origin, recent findings suggest that the pattern and rate of somatic hypermutations in EBV-positive BLs are similar to those found in memory B-cells from peripheral blood [11, 27]. This discrepancy may be due to altered expression of hsa-mir-127 in EBV-positive BL cases compared to EBV-negative cases and normal controls [19, 29]. Upregulation of hsa-mir-127 may lead to downregulation of BLIMP-1 and XBP-1 expression, resulting in persistence of BCL-6 expression and maintenance of the GC phenotype [12]. Additionally, putative targets of hsa-mir-127 have been found to be enriched in an eBL signature [30]. While studies are providing increasing evidence on miRNA deregulation in this tumor, data on hsa-mir-127 remains limited [PMC3432484].